Innovate Articles

Mind and Machine: Navigating the Intellectual Property and Geopolitical Frontiers of Brain-Computer Interfaces

Natasha Voros Alvarado 

Introduction

The integration of Brain-Computer Interface (BCI) technology into the consumer and clinical markets marks a pivotal transition from science fiction to a high-stakes legal reality. As these "wetware" devices evolve from invasive implants to minimally invasive neuro-links, they are simultaneously redefining the boundaries of patentable subject matter and the scope of national security policy. This article explores the current BCI market landscape, spearheaded by pioneers like Neuralink and Synchron, and analyzes the unique obstacles practitioners face under the 35 U.S.C § 101 "mental processes" exception.¹ Beyond the examiner’s desk, we examine the burgeoning "neuro-race" with China and the evolving regulatory framework governing neural data export. By understanding the intersection of technical architecture and geopolitical risk, intellectual property attorneys can better navigate the novel litigation and liability disputes that will inevitably arise as practitioners draft the constitution for the future of human consciousness.

The Current Landscape: From Clinical Necessity to Consumer Utility

Consider the present state of BCI technology, which enables direct communication between the human brain and external electronic devices.² While the most reliable iterations currently range from invasive electrode arrays to minimally invasive vascular stents, biotechnology companies are rapidly increasing the sophistication of these interfaces.³ Initially, the mission was purely therapeutic: restoring communication and motor function to individuals with severe cognitive or physical impairments. However, as research makes significant headway, the intentionality behind BCI use has become increasingly elaborate. Current theories suggest these devices could soon migrate from clinical necessity to daily ubiquity.⁴ Such a shift would trigger a profound social transformation, moving toward a deep reliance on neural-linked technology that renders older, manual interfaces peripheral to modern life.⁵

The stakes of this neurotechnological transition are remarkably high because intellectual property law does not exist in a vacuum. It serves as the functional engine of public policy. When intellectual property cases are adjudicated, the resulting precedents do more than define the law. They shift power between plaintiffs and defendants and influence the very trajectory of future innovation. Technological intellectual property litigation, in particular, informs public opinion and sets the ethical guardrails for what a society is willing to accept.

Leading Devices: The Battle of "Wetware" Architectures

To understand the IP landscape, one must look at the market leaders currently defining the "wetware" era. On one end of the spectrum is Neuralink, with its "Link" device, a fully implantable, cosmetically invisible BCI that requires robotic surgery to thread electrodes into the motor cortex.⁶ On the other is Synchron, which has pioneered a "stentrode" system. Unlike Neuralink, Synchron’s device is delivered via the jugular vein, avoiding the need for a craniotomy.⁷

From an IP perspective, these two approaches represent vastly different patent portfolios. Neuralink’s strategy focuses heavily on the miniaturized electrode threading and the surgical robotics necessary for high-precision implantation, while Synchron’s strength lies in endovascular delivery systems and signal processing within the unique constraints of the blood vessel environment. For the patent practitioner, these differences are critical: a broad claim for "directing a computer via neural signals" is unlikely to survive a 35 U.S.C. § 112 enablement challenge, as the "full scope" of such a claim would require undue experimentation across vastly different hardware modalities.⁸ Instead, the most robust "fences" are those built around the specific mode of entry and proprietary signal-filtration algorithms.

However, the very success of these proprietary architectures in securing FDA breakthroughs and robust patent protection brings us to a new frontier of legal concern. As these devices move from experimental marvels to commercially viable tools, the focus shifts from the right to exclude competitors to the right to include or even mandate users. The technical "fences" that protect multi-billion dollar investments are now intersecting with the ethical boundaries of the workplace and the classroom.

The Patentability Frontier: Navigating Section 101

As BCI technology transitions from clinical trials to consumer markets, led by pioneers like Neuralink, Synchron, and Science, the race for intellectual property protection has intensified. For the patent practitioner, the primary hurdle remains the "Alice/Mayo" framework under 35 U.S.C. § 101. BCIs exist at the precarious intersection of medical diagnostics and computer-implemented software, often triggering rejections for "abstract ideas" or "natural phenomena." In the BCI context, the risk is even higher: is the device merely a conduit for a "mental process"?

The 2026 USPTO guidance on Subject Matter Eligibility Declarations (SMEDs) has provided a roadmap for overcoming these rejections.⁹ By emphasizing the "bio-hybrid interface,” the physical transformation of an analog biological signal into a digital command, practitioners can demonstrate that BCIs are more than just "computers on the brain." They are specialized tools that achieve a result (e.g., controlling a prosthetic limb) that the human mind cannot achieve alone. This "physicality" is the key to surviving Step 2 of the Alice test, transforming an abstract thought into a patentable technological improvement. To secure a robust patent portfolio, firms must move beyond claiming the result (e.g., "moving a cursor with thought") and focus on the technical architecture, the specific signal-to-noise filtration algorithms or the bio-hybrid interface materials that prevent neural scarring.¹⁰

Furthermore, this recent USPTO guidance under Director John Squires has signaled a "policy shift" toward fostering American leadership in emerging tech.¹¹ By streamlining the SMED process, the Office is effectively lowering the barrier to entry for domestic innovators who are often bogged down by the "abstract idea" bottleneck.¹² This shift is not merely administrative; it is a calculated response to the reality that intellectual property is the primary currency in a zero-sum technological game. As the USPTO works to solidify the domestic "patent moat" for American BCI firms, it does so with an eye toward the horizon, recognizing that the strength of a nation’s patent portfolio is increasingly synonymous with its national security. This alignment of IP policy and sovereign interest marks a new era where the examiner's desk becomes a front line in the escalating global competition for neurotechnological supremacy.

"Neural Mandates:" Socioeconomic and Security Risks

The utility value of BCIs currently under development makes them an attractive tool for everyday tasks, as they assess a myriad of neurological signals in real-time to streamline human-computer interaction. However, the prospect of a societal shift toward mandatory BCI adoption—particularly by employers or academic institutions seeking "performance optimization"—presents a looming crisis for bodily autonomy and equal protection.

In response to these concerns, 2026 has seen a surge in "preemptive" state legislation. For example, Washington’s House Bill 2303 now strictly prohibits employers from requiring or even requesting that employees receive subdermal implants as a condition of employment, establishing significant statutory penalties for violations.¹³Furthermore, the use of BCIs for workplace monitoring risks running afoul of the Americans with Disabilities Act (ADA). The Equal Employment Opportunity Commission (EEOC) has signaled that BCI-driven productivity metrics could inherently "screen out" qualified individuals with neurological diverse conditions or disabilities, potentially constituting a violation of the ADA’s restrictions on medical examinations and disability-related inquiries.¹⁴

The legal community must prepare for the "First Wave" of BCI litigation. Under the Restatement (Third) of Torts, it is necessary to ask whether an error in thought-translation constitutes a design defect.¹⁵ If a user’s "intent" is misinterpreted by the BCI, causing a car crash or a surgical error, the black box nature of neural AI will make discovery incredibly difficult.

Beyond the workplace, the "neuroprivacy" landscape is rapidly shifting. States like Colorado and California have recently amended their comprehensive privacy acts to explicitly classify "neural data" as sensitive personal information, requiring heightened consent standards and rigorous data protection assessments before such data can be processed.¹⁶These protections are vital because, unlike traditional biometric data (like fingerprints), neural data is susceptible to "cognitive hacking." Unless future BCIs are designed with end-to-end "neuro-encryption," they remain vulnerable to hackers who could not only steal sensitive thoughts but potentially manipulate a user's subconscious states.¹⁷ Such misuse could result in unprecedented "wetware" torts, where the line between a software bug and a personal injury becomes dangerously blurred, threatening the very profitability and viability of the neurotech industry. These downstream complications make preparing for the imminence of mainstream BCI technology an increasing priority.

Geopolitical Tensions: The "Neuro-Race" with China

Looking beyond our borders, BCIs have become a focal point of national security. The United States’ BRAIN Initiative is now in a direct "intelligence race" with the China Brain Project.¹⁸In Beijing, researchers are not only focused on medical restoration but on "human-machine teaming" for military superiority.¹⁹This raises a terrifying legal question: if a foreign-developed BCI is used by American citizens, who owns the "raw" neural data?

The U.S. Department of Commerce has recently moved to include certain BCI signal-processing algorithms on the Commerce Control List (CCL), effectively treating them as dual-use technologies subject to export controls.²⁰ For IP attorneys in tech hubs like San Francisco and Oakland, this means that filing international patent applications (PCTs) for BCI tech now requires a rigorous "national security review" to ensure that sensitive "neuro-encryption" methods are not inadvertently leaked to adversaries.²¹ Intellectual property specialists are no longer just protecting "gadgets"; lawyers are protecting the sovereignty of the human mind.

The Road Ahead: Liability, Ethics, and Strategy

As BCI technology becomes increasingly complex and pervasive, intellectual property practitioners must ensure that the law does not lag behind innovation. The intersection of patent law, products liability, and national security in the BCI space will define the next decade of legal practice. As patent attorneys, we are not just filing papers; we are drafting the constitution for the future of human consciousness.

Footnotes:

1. Alice Corp. v. CLS Bank Int’l, 573 U.S. 208, 218 (2014) (holding that "abstract ideas," including "mental processes," are not patentable subject matter under 35 U.S.C. § 101).
2. See generally The Future of Brain-Computer Interfaces, YouTube (Mar. 15, 2024), https://www.youtube.com/watch?v=5gspRJVp9dI.
3. See Neurotechnology: The Next Frontier of Human-Computer Interaction, 12 Nature Electronics 401, 403 (2025), https://www.nature.com/articles/s41928-025-0123-x.
4. See The Ethics of Augmentation: BCIs and the Future of Cognitive Liberty, 38 Harv. J.L. & Tech. 215 (2025), https://jolt.law.harvard.edu/articles/ethics-augmentation.
5. See Max Hodak, The Biology of BCI: Beyond Medical Restoration, Science Corp Blog (Jan. 12, 2026), https://science.xyz/blog/biology-of-bci/.
6. Neuralink, The Link: A Fully Implantable BCI, https://neuralink.com/approach/ (last visited Apr. 10, 2026).
7. Synchron, The Stentrode Endovascular Interface, https://synchron.com/technology (last visited Apr. 10, 2026).
8. 35 U.S.C. § 112; see also Amgen Inc. v. Sanofi, 598 U.S. 596, 610-12 (2023) (reaffirming the enablement standard under 35 U.S.C. § 112).
9. See John Squires, Memorandum on Subject Matter Eligibility Declarations under Rule 132, U.S. Pat. & Trademark Off. (Dec. 4, 2025), https://www.uspto.gov/memos/smed-guidance.
10. See generally 2026 Patent Prosecution Trends: Navigating the Wetware Era, IPWatchdog (Feb. 2, 2026), https://ipwatchdog.com/2026/02/patent-trends-bci.
11. See John Squires, Director’s Forum: Fostering American Leadership in Emerging Technologies, USPTO (Feb. 15, 2026), https://www.uspto.gov/blog/directorsforum/fostering-leadership-tech.
12. See USPTO Strategic Plan 2026-2030: Securing the Innovation Frontier, U.S. Pat. & Trademark Off. (Jan. 15, 2026), https://www.uspto.gov/about-us/performance-and-planning/strategic-plan.
13. H.B. 2303, 69th Leg., Reg. Sess. (Wash. 2026) (prohibiting employer-mandated subdermal microchip implants).
14. See Guidance Document: Algorithms, Artificial Intelligence, and Disability Discrimination in Hiring, ADA.gov (Mar. 20, 2026), https://www.ada.gov/assets/pdfs/ai-guidance.pdf.
15. See Restatement (Third) of Torts: Prods. Liab. § 2 (Am. L. Inst. 1998) (defining categories of product defects, including design defects).
16. See H.B. 24-1058, 74th Gen. Assemb., Reg. Sess. (Colo. 2024) (amending the Colorado Privacy Act to include "neural data" as sensitive biological data).
17. See The Rise of Neurotech and the Risks for Our Brain Data, New America (Mar. 28, 2025), https://www.newamerica.org/insights/the-rise-of-neurotech.
18. See Neurotechnology and International Security, 43 Pol. & Life Sci. 112, 115 (2024), https://www.cambridge.org/core/journals/politics-and-the-life-sciences.
19. See Bassem Kahled, The Geopolitics of Technology: Evidence from the Interaction Between the United States and China, 10 Russian J. Econ. 45, 48 (2024), https://rujec.org/article/118505/.
20. Export Administration Regulations: Revisions to the Commerce Control List regarding Neural-Interface Technologies, 91 Fed. Reg. 14,202 (Feb. 12, 2026), https://www.federalregister.gov/documents/2026/02/12/bci-export-controls.
21. See Navigating Export Controls for Silicon Valley Innovators, SF Bar Ass’n IP Section (Mar. 5, 2026), https://www.sfbar.org/ip-export-controls-2026.

AI Disclosure:

Google Gemini was used to help generate key words for topic sub-sections and to conduct precise research for some of the substantive portions of this submission.